Aspira Women?s Health Inc. announced that Ryan Phan, Ph.D., is stepping down as the Company?s Chief Scientific and Operating Officer effective September 15, 2023. Dr. Phan is expected to remain as an advisor for the Company to provide scientific and operational advice related to ongoing product development programs.
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
1.66 USD | +2.47% |
|
+38.79% | -60.54% |
Jul. 09 | Aspira Women's Health Inc. announced that it has received $1.910249 million in funding | CI |
Jul. 02 | Exchange-Traded Funds, Equity Futures Lower Pre-Bell Tuesday Ahead of Powell Speech | MT |
![Consensus](/images/consensus_flch.gif)
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-60.54% | 22.19M | |
-32.73% | 8.68B | |
+25.36% | 3.86B | |
+16.61% | 2.43B | |
-26.46% | 1.84B | |
-7.27% | 1.73B | |
+39.16% | 1.16B | |
+56.17% | 842M | |
-9.17% | 702M | |
-7.86% | 594M |
- Stock Market
- Equities
- AWH Stock
- News Aspira Women's Health Inc.
- Aspira Women?S Health Inc. Announces Resignation of Ryan Phan as Chief Scientific and Operating Officer, Effective September 15, 2023